Shop Now Contact

Anti-Human C5 (Eculizumab Biosimilar)

Cat # Size Price Quantity
5068011 mg$200
5068025 mg$650
50680320 mg$2200

  Bulk/Custom

Product Details

CloneEculizumab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionAnti-Human C5 (Eculizumab Biosimilar)
IsotypeHuman IgG4
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman C5
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life13 months
SynonymsComplement C5
Target NameC5, complement protein C5, Complement component 5, CPAMD4
Antibody TypeRecombinant
Research AreasComplement
See All FormatsClone Eculizumab

Background Information

Eculizumab is a recombinant humanized monoclonal antibody belonging to the immunoglobulin G2/4 hybrid subclass, designed to specifically target the human complement component C5. Structurally, the molecule has a molecular weight of approximately 148 kilodaltons (kDa) and follows the canonical IgG architecture composed of two identical heavy chains and two identical light chains, joined by interchain disulfide bonds to form a Y-shaped configuration. The variable domains of the heavy (VH) and light (VL) chains are derived from murine antibody sequences that confer antigen-binding specificity, while the constant regions are of human origin, allowing compatibility with human immune system components. It is produced in mammalian expression systems such as Chinese Hamster Ovary (CHO) cells, which ensure correct folding, glycosylation, and structural fidelity.

The antigen-binding sites of Eculizumab, formed by the complementarity-determining regions (CDRs) within the VH and VL domains, exhibit high specificity and affinity for a site on complement protein C5. This non-covalent interaction involves hydrogen bonding and hydrophobic contacts that lock onto C5, preventing its enzymatic cleavage by the C5 convertase complex into the fragments C5a and C5b. By blocking this cleavage, Eculizumab effectively stops the formation of the membrane attack complex (MAC; C5b–C9 complex) and inhibits downstream complement cascade activation. This molecular mechanism provides a controlled means of modulating terminal complement activity in biochemical and immunological experiments involving complement-mediated lysis and inflammation.

The Fc (fragment crystallizable) region of Eculizumab is engineered to minimize effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), achieved through its IgG2/4 hybrid design. This structural configuration retains binding to the neonatal Fc receptor (FcRn), extending the antibody’s circulatory half-life by protecting it from lysosomal degradation. Overall, Eculizumab exemplifies precise antibody engineering tailored for high-affinity target binding and selective inhibition of complement activation at the C5 level, serving as a refined model for studying terminal complement regulation and immune effector modulation.

Data Sheets

Anti-Human C5 (Eculizumab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Related Products

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.